Alexander Pym

With an extensive background in molecular microbiology and translational medicine, Alex leads Wellcome’s work on infectious disease, supporting research into ways to reduce the risks and impacts of infectious disease globally.

Alex joined Wellcome from Janssen Pharmaceutical Companies of Johnson & Johnson where he led the discovery and development of new drugs for tuberculosis (TB) and related diseases. Alexander spent his early career working as a doctor in rural South Africa, where he led the district TB control program. After working on some of the first HIV clinical trials of HAART in London he completed a PhD in Molecular Microbiology at the Institut Pasteur in Paris, supported by a Wellcome Research Fellowship. He went on to spend over a decade in South Africa working initially on clinical drug development at the South African Medical Research Council, before leading a translational research group at AHRI.